BG Medicine Nabs Commercial Rights to ACS Biomarker | GenomeWeb
NEW YORK (GenomeWeb News) – Massachusetts-based BG Medicine has acquired exclusive, worldwide rights from ACS Biomarker to develop and commercialize a clinical diagnostic test for acute atherothrombosis, the companies announced yesterday.
 
Scientists at the Cardiovascular Research Institute Maastricht in the Netherlands discovered the biomarker, which BG plans to develop into a test to diagnose transient blockages that cause stroke-like symptoms, coronary artery blockages, and other heart attack and stroke precursors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.